Refractory Dermatomyostitis
Conditions
Brief summary
This study proposes the use of a PET isotope, \[18F\]-Fibroblast Activation Protein Inhibitor-74, for a prospective single-center, single-arm study using MRI imaging for participants with Refractory Dermatomyostitis.
Interventions
DRUG[18F]-FAPI-74
\[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
Sponsors
Farshad Moradi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a prospective, single-center, single-arm study enrolling 21 adult participants to evaluate \[18F\]-FAPI-74 PET/ MRI for assessment of muscle and soft tissue involvement in Dermatomyositis.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with suspected dermatomyositis. 2. Patient must be \> 18 years old. 3. Be willing and able to provide written informed consent for the trial.
Exclusion criteria
1. Women who are pregnant or potentially pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women. 2. Contraindication to MRI or inability to lie flat for 30 min 3. Any serious medical condition that in the opinion of principal investigator could pose significant risk of harm or injury to the patient if they participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of [18F]-FAPI-74 uptake. | up to 1 hour | write the outcome title, how it will be measured. |
Countries
United States
Outcome results
None listed